Navigation Links
Genta Receives NASDAQ Non-Compliance Notice
Date:12/24/2007

BERKELEY HEIGHTS, N.J., Dec. 24 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that the Company has been notified by the Listing Qualifications Staff of The NASDAQ Stock Market that it no longer complies with NASDAQ Marketplace Rule 4450(a)(5), which requires a minimum closing bid price of $1.00 per share. In accordance with Marketplace Rule 4450(e)(2), the Company has until June 16, 2008 to regain compliance, which requires a closing bid price of the Company's common stock at or above $1.00 per share for a minimum of 10 consecutive business days. In the event the Company does not regain compliance within this period, the Company may appeal a delisting determination by the Staff to the NASDAQ Listing Qualifications Panel, and the Company's securities would remain listed pending the Panel's decision.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
11. IsoTis Receives FDA Clearance for Accell Family of Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... PA (PRWEB) October 17, 2014 ... being called upon by health facilities around the ... patients are being treated. Among the many places ... includes Texas Health Presbyterian Hospital Dallas and at ... The state-of-the-art vapor-producing robots have been utilized to ...
(Date:10/17/2014)... The global SWIR market report defines and ... of revenue. This market is valued at $60.1 million ... by 2019, at a CAGR of 10.2% from 2014 ... global SWIR market report, to get an idea of ... of the segmentation of the market, and is supported ...
(Date:10/17/2014)... The North American Knowledge-based/Evidence-based Clinical ... segments the market in North America with analysis ... in North America is expected to reach around ... of 8.1% from 2013 to 2018. , Browse ... clinical decision support system (CDSS) market, to get ...
(Date:10/17/2014)... The Middle East and Africa Location Based Services (LBS) ... Middle East and Africa with analysis and forecast of revenue. ... 2014 to $3,403.1 million by 2019, at a CAGR of ... of the Middle East and Africa Location Based Services (LBS) ... provided. It also provides a glimpse of the market segmentation, ...
Breaking Biology Technology:Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 2Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 3Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 4Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 5Bioquell’s Vapor Producing Robots Selected to Combat Ebola in Hospitals Around the World 6The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 2The global SWIR market is expected to reach $97.9 million by 2019 - New Report by MicroMarket Monitor 3The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 2The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 3The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 4The North American Knowledge-based/Evidence-based Clinical Decision Support System (CDSS) market is expected to reach around $283.3 million by 2018 - MicroMarket Monitor 5The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 2The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 3The Middle East and Africa Location Based Services (LBS) market is estimated to reach $3,403.1 million by 2019 - New Report by MicroMarket Monitor 4
... a long-term reversal of tinnitus, a debilitating hearing impairment ... up to 40 percent of military veterans, according to ... of Nature . Researchers Dr. Michael ... Texas at Dallas and University-affiliated biotechnology firm MicroTransponder report ...
... success of the previous conferences of the series held ... (EPD) conferences are a leading venue for experts from ... as a processing technique for fabrication of both traditional ... electric surface charge on particles in suspension, which migrate ...
... NEOG ) today announced that its rapid test ... the U.S. Food and Drug Administration (FDA) to be equivalent ... sensitivity for detecting SE. The FDA,s determination of ... Reveal for SE to shorten the testing time and comply ...
Cached Biology Technology:Nature article focuses on tinnitus treatment 2Nature article focuses on tinnitus treatment 34th International Conference on Electrophoretic Deposition 24th International Conference on Electrophoretic Deposition 34th International Conference on Electrophoretic Deposition 4Neogen's Rapid Test for Salmonella enteritidis Receives FDA Approval 2
(Date:10/15/2014)... Oct. 15, 2014 Sandata Technologies, LLC, ... and community-based care, today announced it released a ... Santrax® Electronic Visit Verification™ Solution (EVV™)  for Quality ... home health company founded in 1996 and has ... The study details the challenges ...
(Date:10/15/2014)... The book ,Models of Life, is a non-traditional biophysics ... itself. The book is a journey of discovery into ... of life and biological regulation. It is about how ... strategic communication between the billions of cells in an ... the relationships between principles, which can be found on ...
(Date:10/15/2014)... to an unexpected extent. The outbreak does not follow ... shows a new disease dynamic in regions, where it ... German National Academy of Sciences Leopoldina, acatech – the ... of the German Academies of Sciences and Humanities have ... In the statement the academies call for the following ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... that the amount of health-linked polyphenols present during roasting ... and might be used to limit the generation of ... family of naturally occurring plant components that have been ... Flavonoids and some anti-oxidants belong to the polyphenol family ...
... has shown promise in skin disease and hemophilia might one ... new study by researchers at Stanford University School of Medicine. ... the Proceedings of the National Academy of Sciences the week ... a healthy copy of the gene dystrophin into mice with ...
... and Infectious Diseases (NIAID), part of the National ... drug candidate attacks the bacterium that causes tuberculosis ... the National Academy of Sciences, the finding may ... targets Mycobacterium tuberculosis (M. tb). , "PA-824, ...
Cached Biology News:Chemical compound inhibits tumor growth, size in new mouse study 2Chemical compound inhibits tumor growth, size in new mouse study 3Gene therapy for muscular dystrophy fixes frail muscle cells in animal model, Stanford study finds 2Gene therapy for muscular dystrophy fixes frail muscle cells in animal model, Stanford study finds 3NIAID researchers show how promising TB drug works 2NIAID researchers show how promising TB drug works 3
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
Designed for use with the Agencourt CleanSEQ and Agencourt AMPure 384-well SPRI reagent kits. For use with 384-well thermal cycling plates....
...
Biology Products: